Development of a suspension serum-free helper-dependent adenovirus production system and assessment of co-infection conditions

Journal of Virological Methods

Volumn 148, Issue 1-2, 2008, Pages 106-114

  Meneses Acosta, Angélica ^a   Dormond, Edwige ^a   Jacob, Danielle ^a   Tom, Roseanne ^a   Bernier, Alice ^a   Perret, Sylvie ^a   St Laurent, Gilles ^a   Durocher, Yves ^a   Gilbert, Rénald ^a   Kamen, Amine ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Adenovirus; Bioreactor production; Gene therapy; Gutless adenovirus; Helper dependent adenovirus; MOI; Serum free suspension culture

Indexed keywords

ADENOVIRUS; ARTICLE; BIOREACTOR; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SUSPENSION; VIRUS EXPRESSION; VIRUS PARTICLE;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; CELL COUNT; CELL LINE; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; GENETIC VECTORS; HELPER VIRUSES; HUMANS; TRANSDUCTION, GENETIC; VIRUS CULTIVATION;

ADENOVIRIDAE;

EID: 39149102532     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2007.10.017     Document Type: Article

References (49)

1. Alemany R., Dai Y., Lou Y.C., Sethi E., Prokopenko E., Josephs S.F., and Zhang W.W. Complementation of HD adenoviral vectors: size effects and titer fluctuations. J. Virol. Methods 68 (1997) 147-159
2. Bett A.J., Prevec L., and Graham F.L. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67 (1993) 5911-5921
3. Bilbao R., Reay D.P., Wu E., Zheng H., Biermann V., Kochanek S., and Clemens P.R. Comparison of high-capacity and first generation adenoviral gene delivery to murine muscle in utero. Gene Ther. 12 (2005) 39-47
4. Buchholz F., Angrand P.O., and Stewart A.F. Improved properties of FLP recombinase evolved by cycling mutagenesis. Nat. Biotechnol. 16 (1998) 657-662
5. Byrnes A.P., Rusby J.E., Wood M.J.A., and Charlton H.M. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66 (1995) 1015-1024
6. Castro M., Goverdhana S., Hu J., Jovel N., Yuan X., and Lowenstein P. Gene therapy for pituitary tumors: from preclinical models to clinical implementation. Front Neuroendocrinol. 24 (2003) 62-77
7. Coté J., Garnier A., Massie B., and Kamen A. A serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol. Bioeng. 59 (1998) 567-575
8. Dudley R.W., Lu Y., Gilbert R., Matecki S., Nalbantoglu J., Petrof B.J., and Karpati G. Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. Hum. Gene Ther. 15 (2004) 145-156
9. Durocher Y., Perret S., and Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30 (2002) E9
10. Fisher K.J., Choi H., Burda J., Chen S.J., and Wilson J.M. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217 (1996) 11-22
11. Gilbert R., Dudley R.W., Liu A.B., Petrof B.J., Nalbantoglu J., and Karpati G. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum. Mol. Genet. 12 (2003) 1287-1299
12. Gilbert R., Liu A., Petrof B., Nalbantoglu J., and Karpati G. Improved performance of a fully gutted adenovirus vector containing two full-length dystrophin cDNAs regulated by a strong promoter. Mol. Ther. 6 (2002) 501-509
13. Gilbert R., Nalbantoglu J., McHowel J., Davies L., Fletcher S., Amalfitano A., Petrof B., Kamen A., Massie B., and Karpati G. Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by trans-acting adenoviral gene products. Hum. Gene Ther. 12 (2001) 1741-1755
14. Gilbert R., Nalbanoglu J., Tinsley J.M., Massie B., Davies K.E., and Karpati G. Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle. Biochem. Biophys. Res. Commun. 242 (1998) 244-247
15. Hardy S., Kitamura M., Harris-Stansil T., Dai Y., and Phipps M.L. Construction of adenovirus vectors through Cre-lox recombination. J. Virol. 71 (1997) 1842-1849
16. Hu Y.C., and Bentley W.E. Effect of MOI ratio on the composition and yield of chimeric infectious bursal disease virus-like particles by baculovirus co-infection: deterministic predictions and experimental results. Biotechnol. Bioeng. 75 (2001) 104-119
17. Klyushnichenko V., Bernier A., Kamen A., and Harmsen E. Improved high-performance liquid chromatographic method in the analysis of adenovirus particles. J. Chromatogr. B 755 (2001) 27-33
18. Kochanek S., Clemens P.R., Mitani K., Chen H.H., Chan S., and Casey T. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and B-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5731-5736
19. Lin E., and Nemunaitis J. Oncolytic viral techniques. Cancer Gene Ther. 11 (2004) 643-664
20. Lowenstein P.R., and Castro M.G. Recent Advances in the pharmacology of neurological gene therapy. Curr. Opin. Pharmacol. 4 (2004) 1-7
21. McConnell M.J., and Imperiale M.J. Biology of adenovirus and its use as a vector for gene therapy. Hum. Gene Ther. 15 (2004) 1022-1033
22. Mitani K., Graham F.L., Caskey C.T., and Kochanek S. Rescue, propagation and partial purification of a helper virus-dependent adenovirus vector. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3854-3858
23. Molnar M.J., Gilbert R., Lu Y., Liu A.B., Guo A., Larochelle N., Orlopp K., Lochmuller H., Petrof B.J., Nalbantoglu J., and Karpati G. Factors influencing the efficacy, longevity, and safety of electroporation-assisted plasmid-based gene transfer into mouse muscles. Mol. Ther. 10 (2004) 447-455
24. Morsy M.A., Gu M.C., Motzel S., Zhao J., Lin J., Su Q., Allen H., Franlin L., Parks R.J., Graham F.L., Kochanek S., Bett A.J., and Caskey T. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 7866-7871
25. Muruve D.A. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15 (2004) 1157-1166
26. Nadeau I., Gilbert P.A., Jacob D., Perrier M., and Kamen A. Low-protein medium affects the 293SF central metabolism during growth and infection with adenovirus. Biotechnol. Bioeng. 77 (2002) 91-104
27. Nadeau I., and Kamen A. Production of adenovirus vector for gene therapy. Biotechnol. Adv. 20 (2003) 475-489
28. Ng P., Beauchamp C., Evelegh C., Parks R., and Graham F.L. Development of a FLP/frt system for generating HD adenoviral vectors. Mol. Ther. 3 (2001) 809-815
29. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
30. Nyberg-Hoffman C., Shabram P., Li W., Giroux D., and Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 3 (1997) 808-811
31. Palmer D., and Ng P. Improved system for HD adenoviral vector production. Mol. Ther. 8 (2003) 846-852
32. Palmer D.J., and Ng P. Helper-dependent adenoviral vectors for gene therapy. Hum. Gene Ther. 16 (2005) 1-16
33. Parks R.J. Improvements in adenoviral vector technology: overcoming barriers for gene therapy. Clin. Genet. 58 (2001) 1-11
34. Parks R.J., Chen L., Anton M., Sankar U., Rudnicki M.A., and Graham F.L. A HD adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 13565-13570
35. Parks R.J., and Graham F.L. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J. Virol. 71 (1997) 3293-3298
36. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G., Wilson J.M., and Batshaw M.L. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80 (2003) 148-158
37. Reddy P.S., Sakhuja K., Ganesh S., Yang L., Caída D., Brann T., Pattison S., Golightly D., Idamakanti N., Pinkstaff A., Kaloss M., Barjot C., Chamberlain J.S., Kaleko M., and Connelly S. Sustained Human Factor VIII expression in Hemophilia A mice following systemic delivery of gutless adenoviral vector. Mol. Ther. 5 (2002) 63-73
38. Reed L.J., and Muench H. A simple method of estimating fifty per cent endpoints. J. Hyg. 27 (1938) 493-497
39. Rux J.J., and Burnett R.M. Adenovirus structure. Hum. Gene Ther. 15 (2004) 1167-1176
40. Sakhuja K., Reddy P.S., Ganesh S., Cantaniag F., Pattison S., Limbach P., Kayda D.B., Kadan M.J., Kaleko M., and Connelly S. Optimization of the generation and propagation of gutless adenoviral vectors. Hum. Gene Ther. 14 (2003) 243-254
41. Sandig V., Youil R., Bett A.J., Franlin L.L., Oshima M., Maione D., Wang F., Metzker L.M., Savino R., and Caskey C.T. Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 1002-1007
42. Shenk, T., 1996. Adenoviridae: the viruses and their replication. In: Virology. B.N. Fields, D.M. Knipe and P.M. Howley, Eds (Lippincott-Raven, New York) pp. 2111-2148.
43. Soifer H., Higo C., Kazazian Jr. H.H., Moran J.V., Mitani K., and Kasahara N. Stable integration of transgenes delivered by a retrotransposon-adenovirus hybrid vector. Hum. Gene Ther. 12 (2001) 1417-1428
44. Soifer H., Higo C., Logg C.R., Jih L.J., Shichinohe T., Harboe-Schmidt E., Mitani K., and Kasahara N. A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol. Ther. 5 (2002) 599-608
45. Thomas C.E., Schiedner G., Kochanek S., Castro M.G., and Lowenstein P. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7482-7487
46. Umaña P., Gerdes C.A., Stone D., Davis J.R.E., Ward D., Castro M.G., and Lowenstein P.R. Efficient FLPe recombinase enables scalable production of helper dependent adenoviral vectors with negligible helper-virus contamination. Nat. Biotechnol. 19 (2001) 582-585
47. Xie L., Metallo C., Warren J., Pilbrough W., Peletier J., Zhong T., Pikus L., Yancy A., Leung J., Aunins J.G., and Zhou W. Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER. C6 cell culture under sparging conditions. Biotechnol. Bioeng. 83 (2003) 45-52
48. Xu Z.L., Mizuguchi H., Sakurai F., Koizumi N., Hosono T., Kawabata K., Watanabe Y., Yamaguchi T., and Hayakawa T. Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv. Drug Deliver. Rev. 57 (2005) 781-802
49. Yang Y., Li Q., Ertl H.C.J., and Wilson J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69 (1995) 2004-2015